Abstract: Model-Based Design of Experiments (MBDoE) techniques represent a valuable tool to increase the information content of clinical tests with the purpose to identify the set of parameters of physiological models of type 1 diabetes mellitus. However, conventional MBDoE techniques are affected by some limitations. Prior uncertainty in the model parameters and model mismatch may lead the constrained design procedure to predict clinical tests that turn out to be suboptimal or, even worse, unsafe for the subject. Advanced MBDoE techniques, including online model-based redesign of experiments can be used to preserve the effectiveness of the experiment design sessions, exploiting in a more efficient way the nearly-continuous information flux coming from continuous glucose monitoring systems (CGMSs). In this paper a simulated case study is used to assess the impact of advanced redesign techniques on exploiting CGMSs data in the experiment design and successive parameter estimation for the identification of a complex physiological model of glucose homeostasis.
INTRODUCTION
Type 1 diabetes mellitus (T1DM) is a metabolic disease of the glucoregulatory system affecting millions of people worldwide and characterised by the absence of insulin endogenous secretion resulting in the total inability of the subject to adequately regulate his/her blood glucose levels (glycemia). In T1DM care, one of the most promising therapies derives from the use of an artificial pancreas, an external piece of equipment based on a continuous glucose measurement sensor, a control algorithm for the calculation of the appropriate insulin rate, and a micropump for continuous insulin administration. The development of an artificial pancreas is firmly related to the availability of a reliable and detailed physiological model of glucose homeostasis . A model is essential for controller design and tuning and it may become part of the control scheme itself if advanced model-based control strategies are employed ). However, due to the high inter-and intra-variability of the individual responses, a specific difficulty is posed by the need to tailor a generic model to an individual subject by estimating the set of individual model parameters in a statistically sound way. The model identification procedure can be costly and time consuming because the system may exhibit identifiability issues (Saccomani et al., 2003) , or there may be a mismatch between the model and the actual system to be represented (i.e. the subject affected by diabetes), or reliable data may be difficult and expensive to obtain. (Franceschini and Macchietto, 2008) demonstrated to be an efficient tool in a large variety of applications to increase the information content of experiments. In a recent study, Galvanin et al. (2009a) effectively exploited MBDoE to design clinical tests enabling a statistically sound estimation of the individual parametric set of a detailed model of glucose homeostasis. The clinical test can be designed through an optimisation procedure delivering the temporal patterns and quantities of glucose and/or insulin administration, and the sampling schedule of the glucose concentration measurements. Constraints concerning safety and clinical operability can be enforced on the system in order to define simpler, quicker and less invasive test protocols for model identification. The final achievement is the correct identification of the set of individual model parameters representing the metabolic portrait of a subject affected by T1DM.
Model-Based Design of Experiments (MBDoE) techniques
Recent advancements on sensor technology allowed for the development of continuous glucose monitoring systems (CGMSs) where the glucose levels can be continuously measured over a 24-h period. Although CGMSs are known to suffer from accuracy issues (Cengiz and Tamborlane, 2009 ) and a particular difficulty is posed on how to model the CGMS signal (Facchinetti et al., 2010) , CGMSs may open new possibilities to enrich the information content of clinical tests for model identification, thanks to the availability of more frequent measurements. However, these measurementsare usually less precise and accurate than the ones realised through lab glucose concentration measurements of discrete blood samples and a specific effort has to be made to tailor the MBDoE methodology to the specificity of the continuous measurement system (Galvanin et al., 2010a) .
Preliminary studies involving the application in-vivo of conventional MBDoE methodologies including CGMSs (Laguna et al., 2010) show the potential of the technique, but clearly underline some major limitations of the conventional design formulations. First of all, limited preliminary information on model parameters and/or model mismatch may lead to plan scarcely informative (sub-optimal) or unfeasible tests (e.g. tests that may turn to violate the constraints imposed on the system). Secondly, the conventional MBDoE formulations usually consider discrete sampling, whereas CGMSs allow for a nearly continuous (every 5-10 minutes) blood glucose concentration monitoring. Finally, a further limitation is given by the fact that the conventional MBDoE approach usually involves a sequential procedure and data can only be exploited at the end of the test itself, while a large amount of information is in practice, continuously generated during a clinical test.
Advanced MBDoE strategies are required to overcome the aforementioned limitations. Online model-based redesign of experiment (OMBRE) techniques (Galvanin et al., 2009b) have been recently developed to exploit the information as soon as it is generated by the running experiment (thanks to intermediate parameter estimations), with great improvement in terms of design effectiveness and robustness. Furthermore, feasibility as well as optimality of the planned test can be ensured "by design" adopting specific backoffs from constraints (Galvanin et al., 2010b) to take into account parametric uncertainty as well as model mismatch in the mathematical formulation of the constraints equation. The purpose of this simulation study is to discuss the benefits of adopting such advanced MBDoE strategies in order to design a day-long clinical test for the identification of a detailed model of glucose homeostasis adopting a CGMS. In particular, a backoff-based MBDoE is integrated within an OMBRE framework to provide inherent effectiveness and safety to a clinical test designed under model and parametric mismatch. The results will be compared against an MBDoE with discrete measurements as in Galvanin et al. (2009a) , and the relative merits of the different approaches will be discussed.
THE DESIGN METHODOLOGY
Conventional MBDoE procedures are usually carried out in a sequential way and three key activities are required to determine the model parameters: i) the design of the clinical test, usually performed by maximising a measurement function of the expected information (i.e. the information as predicted by the model); ii) the execution of the test according to the planned experimental conditions; iii) the estimation of the model parameters, which provides the statistical assessment of the estimate and where the actual information provided by the experiment (in the form of collected data) is exploited. The design procedure, leading to a progressive reduction of the uncertainty region of the model parameters, can be iterated until either a satisfactory parameter estimation is achieved or the maximum experimental budget is accomplished.
Standard formulation of model-based experiment design
In this study we consider the Hovorka et al. (2004) glucoseinsulin model and here denoted as the Hovorka-Wilinska model (HWM). HWM belongs to the class of dynamic compartmental models represented by a system of differential and algebraic equations in the form
with the set of initial conditions x(0) = x 0 , where x(t) is the N x -dimensional vector of time-dependent state variables, u(t) and w are the time-dependent and time-invariant control variables (of dimensions N u and N w ), respectively, θ is the N θ -dimensional set of unknown model parameters to be estimated, and t is time. The symbol ^ is used to indicate the estimate of a variable (or of a set of variables): thus, y(t) is the vector of measured values of the outputs, while ŷ is the vector of the corresponding values estimated by the model. In this specific case study the time-dependent manipulated inputs u(t) comprise the subcutaneous insulin infusion and the insulin bolus administration, whereas the carbohydrates (CHO) intake can be represented as a time-invariant control variable w. Only one measurable output y(t) is considered which is constituted by the blood glucose concentration. The formulation of the design vector comprises the manipulated inputs u(t) (usually approximated with a discrete function, i.e. piecewise constant, piecewise linear or polynomial), the timeinvariant input w, the test duration , and the set t sp of time instants at which the output variables are sampled (blood sampling schedule). Therefore, the design vector being optimised becomes:
The standard formulation of model-based experiment design aims at decreasing the model parameter uncertainty region predicted a-priori by the model (1) by acting on the experiment design vector φ and solving the following set of equations:
where V θ is the estimated variance-covariance matrix of model parameters, H θ is the dynamic information matrix and ψ in (3) is an assigned measurement function of V θ representing the chosen design criterion (Pukelsheim, 1993) . The optimisation is carried out under a set of constraints on state variables in the form
where C is an N c -dimensional set of constraint functions expressed through the set Γ(t) of (possibly time-varying) active constraints on the state variables x(t). Additionally, an n φ -dimensional set of constraints on the design variables may be present, and is usually expressed assuming lower (superscript l) and upper (superscript u) bounds on the elements of  as
constraining the design to a hyper-rectangular sub-space of the overall design space.
For the system under investigation the formulation of the set of active constraints (4) is related to the preservation of the complex dynamics involved in the metabolic functions (e.g. to the physiology of the glucoregulatory system). The design under constraints problem concerns the identification of the optimal experimental conditions given by (3) subject to (5) and constraints (4) that here simplify to
where Γ 1 and Γ 2 are the time-invariant upper (hyperglycaemia) and lower (hypoglycaemia) bounds on ŷ. Additional constraints in the form (4) concerning the glucose and insulin dynamics (e.g. related to the attainment of basal or reference values at the end of the test) can be introduced. "Normal" glucose levels are not easy to define and universally agreed upon. In this study, the upper and lower glucose concentration thresholds are set to 180 and 60 mg/dL, respectively. In fact, only C 2 is actually a "hard" constraint (i.e. a constraint never to be violated), because hypoglycaemic conditions can severely affect the subject's health even in a short time. On the contrary, short and moderate post-prandial hyperglycaemic conditions can be tolerated while performing an identification test.
The formulation (5) is related to the operability of design and should take into account a set of clinically realizable settings, including: 1. technological and/or safety limitations on the equipment (for instance the insulin administration rate is limited by the pump features); 2. limitations on carbohydrates ingestion (i.e. maximum amount of CHO that can be administered to the subject); 3. limitations on the total amount of insulin administered to the subject during the test (which is related to the body weight of the subject and to the global amount of ingested CHO).
In order to facilitate the dynamic optimisation task, the manipulated inputs are approximated with a piecewise constant function (defined by n z levels and n sw switching times to be optimised). In this specific case study, θ comprises four parameters, representing the insulin sensitivity of distribution/transport (θ 1 ), the insulin sensitivity of disposal (θ 2 ), the insulin sensitivity of endogenous glucose production (EGP) (θ 3 ), and the EGP extrapolated to zero insulin concentration (θ 4 ).
Continuous model-based design of the clinical test
Conventional MBDoE techniques are based on the assumption that the information is acquired from the experiment through discrete collection (sampling) of data. Consequently, the expected dynamic information being maximised in the standard MBDoE formulation (3) is expressed through discrete forms of the Fisher information matrix (FIM):
In (7) s ij is the ij-th element of the N y ×N y inverse matrix of measurement errors (usually modelled to define the expected precision of the measurements) and 0  H is the prior dynamic information matrix, taking into account the preliminary statistical information about the parametric system before each trial is carried out. The frequent sampling due to a CGMS determines that the measure of the actual information gained from the experiment can be approximated by a continuous profile over the experimental horizon, so that the optimal clinical test design problem can be formulated as:
where M(t) is a time-dependent form for the FIM. The benefit of adopting (8) as the design objective function comes from the fact that the metric of the expected information becomes continuous as the measurement system itself, thus allowing for a continuous exploitation of the available information. Basically, criterion (8) aims at maximising the area underneath the curve of the dynamic expected information, devising a limiting condition for the expected information that cannot be reached unless the sampling frequency approaches infinity (Galvanin et al., 2010a) .
Online redesign of the clinical test
OMBRE exploits intermediate parameter estimation sessions to narrow the confidence interval of the estimated model parameters, and to partially redesign the clinical test while it is being executed. Different OMBRE configurations can be adopted depending on the online updating policy. In this work the test is divided into a number of equally lasting (2 hours) sub-tests; at the end of each sub-test an update of the design variables is scheduled, when a parameter estimation session and a sub-test redesign are carried out in sequence. In an OMBRE approach an experimental test can be adjusted as soon as experimental evidence about the system being modelled becomes available and this can implicitly reduce the risk of unsafe or uninformative experimental conditions, making the test safer and more informative. However, the model mismatch is not dealt with explicitly, and severe hypoglycaemic conditions may occur especially at the beginning of the test, when the model prediction could be strongly inaccurate.
In order to avoid unfeasible solutions "by design" a backoff from active constraints can be introduced within a standard MBDoE framework. The OMBRE optimisation problem including backoff is the solution of (3) (or (8) if a continuous design approach is attempted) subject to (5) and to the feasibility conditions
. (9) β is a backoff realised to preserve the subject from hypoglycaemia during each sub-test, defined as 
whereˆy  is the estimated standard deviation of the glucose response evaluated from parameter estimation at the actual experimental settings before each sub-test is redesigned. After each OMBRE sub-test is performed, a parameter estimation session and a sub-test redesign are carried out in sequence, updating both the uncertainty domain of model parameters (necessary to describe a new backoff) and the optimal experimental conditions (in order to maximise the information content within the subsequent sub-test). The backoff strategy allows enforcing or relaxing the active constraints to meet the safety requirements when the test is performed on the subject.
CASE STUDY
Following Galvanin et al. (2009) , an MBDoE approach is applied to a diabetic subject modelled using HWM (age 56, body weight = 78 kg). The purpose is to estimate precisely the set θ of model parameters using a properly designed daylong test, which is articulated into two distinct phases: i) an overnight preliminary phase, in which the subject's glycaemia is normalised at around 90 mg/dL until 8 AM (this 8-hour test is carried out with the purpose to achieve an initial rough estimate of the model parameters); ii) a second phase comprising four meals (scheduled at 8:00 AM, 12:00 AM, 4:00 PM and 8:00 PM) where the insulin administration as well as the carbohydrates content of four liquid meals are optimised by design. The preliminary phase is the same for all design configurations.
The identification test involves multiple intakes of glucose solution and the management of subcutaneous insulin bolus and infusion. The optimisation variables are the CHO content of the four meals (allowed values are within the range 5-150 g CHO ) and the insulin administration u(t), modelled as
where u S is the insulin infusion rate (approximated with a piecewise constant function where the insulin level can be switched only every 2 hours),D g,i is the CHO content of the ith meal and u bol represents the insulin bolus administration, expressed through the Dirac impulse δ(t) and here managed according to an insulin/CHO ratio. The design optimises the "relaxing factors" k i (i.e., k  ) while, according to Gross et al. (2003) , α= 52.63 mU/g CHO represents a recommended value for the insulin/CHO ratio.
Safe conditions must be guaranteed at all times during the clinical test. Hence the design procedure is carried out with the following constraints on blood glucose concentration: 1. interior constraints on the glycaemic curve to ensure normoglycaemia at all times (60-180 mg/dL); 2. an end-point constraint on the glucose concentration (80-120 mg/dL); 3. a constraint on the final derivative of the glucose concentration to ensure steady glycaemia at the end of the test (-0.01 < Ġ < 0.01 mg/dL/min).
To improve numerical robustness, parameters are normalised with respect to the true values describing the subject and will be indicated as Θ. The condition of the diabetic subject is defined by the parametric set Θ = [1.000 1.000 1.000 1.000] T . At the beginning of the procedure, the initial guess for the parameters is Θ 0 = [2.000 2.000 2.000 2.000] T and no apriori statistic information is supposed to be available in advance. After the 8-hour overnight preliminary phase, the parameter estimates are given by 0  = [2.761 0.854 1.152 1.252] T , which represent the initial set of parameters used in the design of the second phase The following design configurations are proposed and discussed: 1. MBDoE: standard D-optimal design of the test adopting (3) as the objective function and the constraints equation in the (4) and (5) form; the design also optimises the time allocation of n sp = 20 samples obtained by discrete measurements (the minimum time allowed between two consecutive samples is 5 min); 2. OMBRE-B: online redesign of the test with backoff and adopting a D-optimal continuous approach (8) as the objective function, and under the (5) and (9) set of active constraints; it is supposed that the measurements from a CGMS are available very frequently (every 5 min).
It is assumed that the "synthetic" glucose measurements (obtained by simulation of HWM at Θ) are modelled as follows: a. discrete sampling: blood glucose measurements are corrupted by Gaussian noise with zero mean and a constant relative deviation of 0.03; b. CGMS: following Hann et al. (2009) , the measurements are supposed to be affected by a 7% low frequency modelling error added to a 18 % Gaussian mean error:
  2π 1 0.18 1 0.07 cos 82
where y is the measured response and y true is the true interstitial glucose concentration of the simulated subject.
Note that scenario (a) closely resembles the high accuracy of glucose meters that can be reached in ICU ambulatory settings, whereas scenario (b) is closer to the level of precision currently provided by CGMSs. The results from different design configurations are compared in terms of estimated profiles and a-posteriori statistics obtained after a maximum likelihood parameter estimation task is carried out.
Standard MBDoE
A standard design provides an identification test where the actual glycemic response of the subject is pushed beyond the upper glycemic threshold in the second postprandial phase (diamonds, Figure 1 ). This moderate hyperglycaemic condition may be tolerated for model identification purposes but, as an effect of parametric mismatch, the test also turns out to violate the end-point constraints on glycaemia rate-ofchange. The results in terms of optimal insulin administration and optimal CHO content of the meals are shown in Figure 2 .
Results in terms of parameter estimation and a-posteriori statistics obtained after the execution of the optimally designed test are illustrated in Table 1 . The estimation of Θ 3 is not statistically satisfactory. 
Online redesign of the clinical test
A redesign of the clinical test is carried out where the optimal inputs are updated every 2 hours and CGMS data are acquired during the whole duration of the test. A moderate postprandial hyperglycaemia is still realised at the beginning of the designed phase (Figure 3 ), but in this case the endpoint constraints are satisfied. Note how the optimal inputs determined by OMBRE-B (Figure 4 ) are totally different from the ones realised by MBDoE. In particular, OMBRE-B calls for the ingestion of a higher amount of CHO in the first two meals and, accordingly, the release of a larger bolus amount. As a result, the whole available glycaemic range is exploited during the test execution, but the test remains safe for the subject also in the presence of model mismatch, thanks to the backoff action. The CPU time required during each redesign step (carried out on a Pentium D 3Ghz 2GB RAM workstation) is ~5 min. Figure 4 . OMBRE-B: optimal profile of the insulin infusion rate (normalised to 20 mU/min), insulin bolus amount (normalised to 4 U) and CHO content of the meals.
Results in terms of parameter estimation at the end of the test and at 4:00 PM (i.e. after only τ = 16 hours) are shown in Table 2 . Interestingly, it clearly appears how the last 8 hours of the test are essentially used to improve the precision of the Θ 1 estimate, whose accuracy is largely affected by the model mismatch. However, when a redesign strategy is attempted, a statistically sound parameter estimation can be reached well before the scheduled test conclusion (4:00 PM against 12:00 PM) so that the test duration could be shortened thus reducing the stress for the subject. Even if not shown here for the sake of conciseness, it was verified that a simple redesign approach with no backoff action would provide an even statistically better confidence on parameter estimation after 16 hours, but at the cost of an unfeasible test (the subject approaches hypoglycaemia during the first postprandial phase of the test). 
FINAL REMARKS
MBDoE techniques represent a valuable support to increase the information content of clinical tests for the identification of T1DM models. However these techniques, at least in their standard formulation, are not sufficient to ensure both the feasibility and the optimality of the planned test even when discrete but precise measurements are available. Conversely, advanced design techniques involving the online redesign of the clinical test allows exploiting in a better way the "nearlycontinuous" sampling of CGMSs. For identification tests these measurement systems usually provide frequent but considerably less accurate glucose concentration values than the off-line measurement of discrete samples. The information within CGMS data and progressively acquired from the running test can thus be exploited to improve the design prediction while specific backoffs from constraints are enforced to ensure the feasibility of the planned test. Preliminary results show how these advanced design techniques can be successfully adopted to tackle the identification problem, and to increase the information content of the planned tests devising alternative, less invasive and shorter test protocols adopting CGMSs.
